Table 8.
Compound | Treatment | Tmax (min) | Cmax (ng/mL) | AUClast (ng·h/mL) | AUClast a Ratio |
---|---|---|---|---|---|
6G | −βgd | 120 | 27.18 | 37.71 | - |
+βgd | 30 | 12,473 | 13,621 | 361 | |
+KTZ −βgd | 30 | 256.7 | 300.2 | 8 | |
+KTZ +βgd | 30 | 10,061 | 18,782 | 498, 63 b | |
8G | −βgd | NR C | 0.00 | 0.00 | - |
+βgd | 30 | 948.2 | 697.6 | 698 | |
+KTZ −βgd | 30 | 45.68 | 59.10 | 59 | |
+KTZ +βgd | 30 | 1071 | 1330 | 1330, 23 b | |
10G | −βgd | 30 | 55.95 | 61.80 | - |
+βgd | 30 | 740.2 | 634.7 | 10 | |
+KTZ −βgd | 30 | 79.00 | 174.4 | 3 | |
+KTZ +βgd | 30 | 1755 | 1952 | 32, 11 b | |
6S | −βgd | 10 | 3.880 | 1.924 | - |
+βgd | 5 | 143.0 | 126.5 | 66 | |
+KTZ −βgd | 60 | 12.44 | 15.08 | 8 | |
+KTZ +βgd | 30 | 228.6 | 212.5 | 110, 14 b |
−βgd: plasma samples without β-glucuronidase treatment; +βgd: plasma samples treated with β-glucuronidase; +KTZ −βgd: ketoconazole co-administered group plasma samples without β-glucuronidase treatment; +KTZ +βgd: ketoconazole co-administered group plasma samples treated with β-glucuronidase; data presented up to 4 significant digits for Cmax and AUClast; a AUClast ratio calculated considering GE group untreated with βgd as reference; b AUClast ratio calculated considering GE group co-administered with KTZ untreated with βgd as reference; c NR: not reportable, Cmax: peak plasma concentration; AUClast: Area under the curve; n = 3 per time point; mean values reported.